Response
Drs Koutsojannis and Kounis suggest that the fatal anaphylactic reactions associated with lepirudin reexposure are typical examples of allergic acute coronary syndrome (ACS). Although there is no doubt that the cardiac events occurring in the lepirudin-treated patients are associated with an immune reac-tion, their clinical course differs from the typical cases of allergic ACS reported and referenced by Dr Kounis. In allergic ACS, the delay between the onset of allergic symptoms and ACS ranges from 1 to 24 hours. In contrast, the reaction toward lepirudin occurred within minutes. The concept of allergic ACS is based on the release of enzymes from activated mast cells and leukocytes that digest the upper layer of the plaque, facilitating plaque rupture. Although this concept is certainly compatible with a delayed onset of cardiac symptoms after the start of the allergic reaction, it does not fit with the immediate onset of ACS in lepirudin-treated patients. The close correlation of anaphylactic reaction and ACS would be more compatible with cardiac decompensation during a hypotensive episode.
The authors recommend anti-lepirudin antibody testing and skin testing before lepirudin reexposure. In our opinion, this will not provide useful information. More than 40% of lepirudintreated patients will develop anti-lepirudin antibodies of the IgG class, which persist for many months. 1 Antibody testing would, therefore, have a very low predictivity for anaphylaxis. Furthermore, in 2 patients with anaphylactic reactions during lepirudin reexposure, the immunoglobulin class of the anti-lepirudin antibodies has been assessed. In both patients IgG antibodies were found, but no IgE anti-lepirudin antibodies were found, 2,3 and in one of the patients, skin tests were negative despite a clear anaphylactic reaction during reexposure.
Clinically relevant is the fact that severe anaphylaxis to date has always occurred directly after a bolus of lepirudin. Patients receiving a lower dose 2 or an intravenous infusion during hemodialysis 3 had much milder symptoms. This observation supports the concept that in preimmunized patients, a large dose of antigen results in immune complexes that induce an acute reaction via Fc-receptor-dependent release of mediators of anaphylaxis, ie, a dose-dependent, IgG-mediated acute type of anaphylaxis. Therefore, we recommend that a bolus of lepirudin be avoided and that one should start with a reduced intravenous infusion (0.1 mg/kg bw/h). This should reduce the risk of severe anaphylaxis and also the risk of lepirudin overdosing in patients with renal insufficiency. 4
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